Literature DB >> 22581974

Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.

Antonio C Wolff, M Elizabeth Hammond, Daniel F Hayes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22581974     DOI： 10.1093/jnci/djs243

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  8 in total

1.  Defining breast cancer intrinsic subtypes by quantitative receptor expression.

Authors:  Maggie C U Cheang; Miguel Martin; Torsten O Nielsen; Aleix Prat; David Voduc; Alvaro Rodriguez-Lescure; Amparo Ruiz; Stephen Chia; Lois Shepherd; Manuel Ruiz-Borrego; Lourdes Calvo; Emilio Alba; Eva Carrasco; Rosalia Caballero; Dongsheng Tu; Kathleen I Pritchard; Mark N Levine; Vivien H Bramwell; Joel Parker; Philip S Bernard; Matthew J Ellis; Charles M Perou; Angelo Di Leo; Lisa A Carey
Journal:  Oncologist       Date:  2015-04-23

2.  X chromosome gain is related to increased androgen receptor expression in male breast cancer.

Authors:  Enrico Di Oto; Giovanni B Biserni; Zsuzsanna Varga; Luca Morandi; Maria C Cucchi; Riccardo Masetti; Maria P Foschini
Journal:  Virchows Arch       Date:  2018-05-25       Impact factor: 4.064

3.  Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis.

Authors:  Jimmy Ln Vo; Lirong Yang; Samantha L Kurtz; Sean G Smith; Bhanu Prasanth Koppolu; Sruthi Ravindranathan; David A Zaharoff
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

4.  Nomogram for prediction of level 2 axillary lymph node metastasis in proven level 1 node-positive breast cancer patients.

Authors:  Yanlin Jiang; Hong Xu; Hao Zhang; Xunyan Ou; Zhen Xu; Liping Ai; Lisha Sun; Caigang Liu
Journal:  Oncotarget       Date:  2017-08-22

5.  Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer.

Authors:  Xudong Zhu; Jinqi Xue; Xi Gu; Guanglei Chen; Fangning Cao; Huilian Shan; Dan Wang; Xinbo Qiao; Caigang Liu; Yixiao Zhang
Journal:  J Cancer       Date:  2019-09-07       Impact factor: 4.207

6.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2013-10-07       Impact factor: 5.534

7.  Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues.

Authors:  Anna Sapino; Margherita Goia; Daniele Recupero; Caterina Marchiò
Journal:  Front Oncol       Date:  2013-05-21       Impact factor: 6.244

8.  Comparative study between quantitative digital image analysis and fluorescence in situ hybridization of breast cancer equivocal human epidermal growth factor receptors 2 score 2(+) cases.

Authors:  Essam Ayad; Mina Mansy; Dalal Elwi; Mostafa Salem; Mohamed Salama; Klaus Kayser
Journal:  J Pathol Inform       Date:  2015-06-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.